GSK Looks To Capitalize On AstraZeneca’s Anemia Drug Knock-Back

Safety Profile Will Be Battleground

 
• By Andrew McConaghie
Entrance to FDA headquarters in Maryland
After a near-unanimous vote against approval from experts, the US FDA looks likely to reject roxadustat.

More from Business

More from Scrip